Optimization of measurement-based care (OMBC) for depression based on all-round and continuous assessment: rationale and protocol for a multicenter randomized control clinical trial

Table 2 Overview of the acute phase interview

	Acute phase
	0	Week 2, day 14 (± 3)	Week 4, day 28 (± 3)	Telephone interview (week 6)	Week 8, day 56 (± 3)	Telephone interview, week 10 (for patients who change drugs in week 4)	Week 12 (± 7)/early termination
Informed consent	×
Inclusion/exclusion criteria	×
General data	×
Medical history and mental symptoms	×
MINI	×
Somatic and neurological examination	×
Vital signs/weight	×		×		×
QIDS-SR 16	×	×	×	×	×	×	×
FIBSER	×	×	×	×	×	×	×
PDQ-9	×		×		×		×
SDS	×		×		×		×
FBS	×		×		×		×
Q-LES-Q-SF	×		×		×		×
HAMD-17	×		×		×		×
YMRS	×		×		×		×
Acceptability/feasibility		×	×		×		×
Adverse reactions	×	×	×	×	×		×
Biological sample collection	×	×					×

MINI Mini-International Neuropsychiatric Interview, QIDS-SR 16 16-item Quick Inventory of Depressive Symptomatology–Self-Report, FIBSER Frequency, Intensity, and Burden of Side Effects Rating scale, PDQ-9 Patient Health Questionnaire-9, SDS Self-Rating Depression Scale, FBS Family Burden Scale of Disease, Q-LES-Q-SF Quality of Life Enjoyment and Satisfaction Questionnaire–Short Form, HAMD-17 17-Item Hamilton Rating Scale for Depression, YMRS Young Mania Rating Scale

ISSN: 1745-6215